FeaturedMedia Release
Race reveals new strategy for cancer drug Bisantrene
Race Oncology has revealed its new “5 Path” clinical development strategy for its cancer drug,
FeaturedMedia Release
Dr Daniel Tillett joins Race Board
Prominent biotechnology investor and substantial Race shareholder, Dr Daniel Tillett, has
FeaturedMedia Release
Prominent biotech investor leads investment in Race
Race Oncology Limited is pleased to announce the successful completion of a $1.45 million
FeaturedMedia Release
Race announces additional US Patent for Bisantrene
Race Oncology has announced it has secured a new patent on its cancer drug, Bisantrene, from
FeaturedMedia Release
Race’s Israel trial treats first patient with Bisantrene
Race Oncology is pleased to announce the first patient has been treated with Bisantrene in the
FeaturedMedia Release
Investigational New Drug application filed with FDA
Race Oncology has announced the US Food and Drug Administration has received its
FeaturedMedia Release
Principal Investigator appointed for Bisantrene trial
Race Oncology is pleased to announce that Dr Roland Walter has agreed to be the Principal
FeaturedMedia Release
Race appoints leading haematologist to support Bisantrene
Race Oncology is pleased to announce that it has executed a consulting agreement with Professor
FeaturedMedia Release
Race reaches agreement with TrueMed for Bisantrene sales in Israel
Race Oncology is very pleased to announce that it has executed a Named Patient Program (NPP)
FeaturedMedia Release
Race appoints BioSynergy to pursue Bisantrene licensing
Race Oncology is pleased to announce it has executed a services agreement with BioSynergy